Rita Mitnacht-Kraus

This inventor holds 17 USPTO granted patents and 6 published patent applications, plus 5 CIPO patents and 12 EPO patents. Top assignees: Astellas Pharma Gmbh, Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh, Ganymed Pharmaceuticals Ag. Active years: 2015-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rita Mitnacht-Kraus. Retrieved from https://idiyas.com/inventor/rita-mitnacht-kraus

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 6)

% Patents Active = 82.4

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 12 (Patent Applications = 21)

Average Co-Inventor Count = 5.3

ph-index = 5

Forward Citations = 77(Granted Patents)

Location History:

Bad Vilbel, DE (2015)
Friedberg, DE (2016 - 2024)

Company Filing History:

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

patents

7 out of 51

Ganymed Pharmaceuticals Ag

patents

4. 3 out of 14

Tron-Translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz

patents

5. 1 out of 1

Tron - Translationale Onkologie an Der Universitatsmedizin Der Johannes

patent

6. 1 out of 1

Tron - Translationale Onkologie an Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Gemeinn Ggmbh

patent

7. 1 out of 3

Tron Translationale Onkologie an Der Universitatsm

patents

8. 1 out of 1

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat at Mainz Gemeinnutzige Gmbh

patent

9. 1 out of 16

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Ggmbh

patents

where one patent can have more than one assignee

Years Active: 2015-2026

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760115 - ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS (2026-10-13),

2. 12059464 - Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer (2024-08-13),

3. 11976130 - Antibodies against claudin 18.2 useful in cancer diagnosis (2024-05-07),

4. 11919951 - Antibodies useful in cancer diagnosis (2024-03-05),

5. 11826402 - Combination therapy involving antibodies against claudin 18.2 for treatment of metastatic pancreatic adenocarcinoma (2023-11-28),

6. 11541127 - Drug conjugates comprising antibodies against claudin 18.2 (2023-01-03),

7. 11279757 - Antibodies useful in cancer diagnosis (2022-03-22),

8. 10946069 - Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer (2021-03-16),

9. 10813996 - Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer (2020-10-27),

10. 10596256 - Monoclonal anti-GT 468 antibodies for treatment of cancer (2020-03-24),

11. 10314890 - Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer (2019-06-11),

12. 10053512 - Antibodies against claudin 18.2 useful in cancer diagnosis (2018-08-21),

13. 10022444 - Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer (2018-07-17),

14. 9770487 - Combination therapy involving antibodies against Claudin 18.2 for treatment of pancreatic adenocarcinoma (2017-09-26),

15. 9512232 - Antibodies against Claudin 18.2 useful in cancer diagnosis (2016-12-06),

Title: Rita Mitnacht-Kraus: Pioneering Innovator Inspiring the Future

Introduction: Rita Mitnacht-Kraus, a renowned inventor hailing from Friedberg, DE, is a trailblazer in the field of technology, continuing to ignite passion for innovation among aspiring inventors worldwide.

Latest Patents: With an impressive portfolio of 15 patents, Rita Mitnacht-Kraus's recent inventions include "Antibodies against claudin 18.2 useful in cancer diagnosis" and "Antibodies useful in cancer diagnosis," showcasing her commitment to advancing cancer diagnostics through cutting-edge antibody technology.

Career Highlights: Throughout her illustrious career, Rita Mitnacht-Kraus has made significant contributions to the industry, with notable stints at leading companies such as Astellas Pharma GmbH and Ganymed Pharmaceuticals AG. Her innovative spirit and dedication to excellence have earned her recognition as a key figure in driving technological advancements.

Collaborations: Collaborating with esteemed colleagues such as Ugur Sahin and Ozlem Tureci, Rita Mitnacht-Kraus has fostered a culture of creativity and collaboration, leading to groundbreaking inventions that have revolutionized the landscape of cancer diagnosis and treatment.

Conclusion: Rita Mitnacht-Kraus stands as a beacon of inspiration for the next generation of inventors, showcasing the transformative power of innovation in shaping the future of various industries. Her pioneering work in the field of technology continues to impact lives and drive progress, leaving a lasting legacy that will inspire generations to come.

Profile summary based on public USPTO records.